Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Bruce D. Cheson, Peter L. Greenberg, John M. Bennett, Bob Lowenberg, Pierre W. Wijermans, Stephen D Nimer, Antonio Pinto, Miloslav Beran, Theo M. De Witte, Richard M. Stone, Moshe Mittelman, Guillermo F. Sanz, Steven D. Gore, Charles A. Schiffer, Hagop Kantarjian

Research output: Contribution to journalArticle

917 Citations (Scopus)

Abstract

The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge for evaluating response to treatment. Therapeutic trials in MDS have used various criteria to assess results, making cross-study comparisons problematic. In 2000, an International Working Group (IWG) proposed standardized response criteria for evaluating clinically significant responses in MDS. These criteria included measures of alteration in the natural history of disease, hematologic improvement, cytogenetic response, and improvement in health-related quality of life. The relevance of the response criteria has now been validated prospectively in MDS clinical trials, and they have gained acceptance in research studies and in clinical practice. Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria.

Original languageEnglish
Pages (from-to)419-425
Number of pages7
JournalBlood
Volume108
Issue number2
DOIs
StatePublished - Jul 15 2006
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Health
Hematologic Diseases
Cytogenetics
Chromosome Aberrations
Quality of Life
Clinical Trials
Research
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Cheson, B. D., Greenberg, P. L., Bennett, J. M., Lowenberg, B., Wijermans, P. W., Nimer, S. D., ... Kantarjian, H. (2006). Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108(2), 419-425. https://doi.org/10.1182/blood-2005-10-4149

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. / Cheson, Bruce D.; Greenberg, Peter L.; Bennett, John M.; Lowenberg, Bob; Wijermans, Pierre W.; Nimer, Stephen D; Pinto, Antonio; Beran, Miloslav; De Witte, Theo M.; Stone, Richard M.; Mittelman, Moshe; Sanz, Guillermo F.; Gore, Steven D.; Schiffer, Charles A.; Kantarjian, Hagop.

In: Blood, Vol. 108, No. 2, 15.07.2006, p. 419-425.

Research output: Contribution to journalArticle

Cheson, BD, Greenberg, PL, Bennett, JM, Lowenberg, B, Wijermans, PW, Nimer, SD, Pinto, A, Beran, M, De Witte, TM, Stone, RM, Mittelman, M, Sanz, GF, Gore, SD, Schiffer, CA & Kantarjian, H 2006, 'Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia', Blood, vol. 108, no. 2, pp. 419-425. https://doi.org/10.1182/blood-2005-10-4149
Cheson, Bruce D. ; Greenberg, Peter L. ; Bennett, John M. ; Lowenberg, Bob ; Wijermans, Pierre W. ; Nimer, Stephen D ; Pinto, Antonio ; Beran, Miloslav ; De Witte, Theo M. ; Stone, Richard M. ; Mittelman, Moshe ; Sanz, Guillermo F. ; Gore, Steven D. ; Schiffer, Charles A. ; Kantarjian, Hagop. / Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. In: Blood. 2006 ; Vol. 108, No. 2. pp. 419-425.
@article{776655f40cff482896382ebd2353e996,
title = "Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia",
abstract = "The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge for evaluating response to treatment. Therapeutic trials in MDS have used various criteria to assess results, making cross-study comparisons problematic. In 2000, an International Working Group (IWG) proposed standardized response criteria for evaluating clinically significant responses in MDS. These criteria included measures of alteration in the natural history of disease, hematologic improvement, cytogenetic response, and improvement in health-related quality of life. The relevance of the response criteria has now been validated prospectively in MDS clinical trials, and they have gained acceptance in research studies and in clinical practice. Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria.",
author = "Cheson, {Bruce D.} and Greenberg, {Peter L.} and Bennett, {John M.} and Bob Lowenberg and Wijermans, {Pierre W.} and Nimer, {Stephen D} and Antonio Pinto and Miloslav Beran and {De Witte}, {Theo M.} and Stone, {Richard M.} and Moshe Mittelman and Sanz, {Guillermo F.} and Gore, {Steven D.} and Schiffer, {Charles A.} and Hagop Kantarjian",
year = "2006",
month = "7",
day = "15",
doi = "10.1182/blood-2005-10-4149",
language = "English",
volume = "108",
pages = "419--425",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

AU - Cheson, Bruce D.

AU - Greenberg, Peter L.

AU - Bennett, John M.

AU - Lowenberg, Bob

AU - Wijermans, Pierre W.

AU - Nimer, Stephen D

AU - Pinto, Antonio

AU - Beran, Miloslav

AU - De Witte, Theo M.

AU - Stone, Richard M.

AU - Mittelman, Moshe

AU - Sanz, Guillermo F.

AU - Gore, Steven D.

AU - Schiffer, Charles A.

AU - Kantarjian, Hagop

PY - 2006/7/15

Y1 - 2006/7/15

N2 - The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge for evaluating response to treatment. Therapeutic trials in MDS have used various criteria to assess results, making cross-study comparisons problematic. In 2000, an International Working Group (IWG) proposed standardized response criteria for evaluating clinically significant responses in MDS. These criteria included measures of alteration in the natural history of disease, hematologic improvement, cytogenetic response, and improvement in health-related quality of life. The relevance of the response criteria has now been validated prospectively in MDS clinical trials, and they have gained acceptance in research studies and in clinical practice. Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria.

AB - The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge for evaluating response to treatment. Therapeutic trials in MDS have used various criteria to assess results, making cross-study comparisons problematic. In 2000, an International Working Group (IWG) proposed standardized response criteria for evaluating clinically significant responses in MDS. These criteria included measures of alteration in the natural history of disease, hematologic improvement, cytogenetic response, and improvement in health-related quality of life. The relevance of the response criteria has now been validated prospectively in MDS clinical trials, and they have gained acceptance in research studies and in clinical practice. Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria.

UR - http://www.scopus.com/inward/record.url?scp=33745968917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745968917&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-10-4149

DO - 10.1182/blood-2005-10-4149

M3 - Article

C2 - 16609072

AN - SCOPUS:33745968917

VL - 108

SP - 419

EP - 425

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -